e-learning
resources
Amsterdam 2015
Sunday, 27.09.2015
New data on established treatments for asthma and COPD
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Glycopyrronium significantly improves lung function, dyspnea and health status in COPD patients in all GOLD groups
Anthony D. D'Urzo (Toronto, Canada), Anthony D’Urzo, Giovanni Bader, Pablo Altman, Pankaj Goyal
Source:
International Congress 2015 – New data on established treatments for asthma and COPD
Session:
New data on established treatments for asthma and COPD
Session type:
Thematic Poster Session
Number:
1009
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Anthony D. D'Urzo (Toronto, Canada), Anthony D’Urzo, Giovanni Bader, Pablo Altman, Pankaj Goyal. Glycopyrronium significantly improves lung function, dyspnea and health status in COPD patients in all GOLD groups. Eur Respir J 2015; 46: Suppl. 59, 1009
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Management of Severe Asthma in Pediatric Patients by an Interdisciplinary Team in a Public Hospital Setting.
Impact of Dexamethasone on pathogen profile of COVID-19 patients requiring intensive care: a multicentre retrospective study
Related content which might interest you:
Glycopyrronium (GLY) and tiotropium (TIO) comparison: Lung function, dyspnea and health status in COPD patients in all GOLD groups
Source: International Congress 2015 – New data on established treatments for asthma and COPD
Year: 2015
Patients with severe COPD show significant improvements in dyspnea and lung function with once-daily QVA149: The BLAZE study
Source: Annual Congress 2013 –New clinical trials of asthma and COPD drugs
Year: 2013
QVA149 improves lung function and reduces exacerbations compared to tiotropium in patients with severe-to-very severe COPD: The SPARK study
Source: Annual Congress 2013 –Asthma and COPD management: novel clinical findings
Year: 2013
GLISTEN Study subanalysis: Glycopyrronium differentially improves lung function, health status and rescue medication use when added to salmeterol/fluticasone in COPD severity groups
Source: International Congress 2015 – New data on established treatments for asthma, COPD and bronchiectasis
Year: 2015
Irisin is associated with severe exacerbations of COPD independently of lung function, comorbidities and exercise capacity
Source: International Congress 2015 – Notable abstracts in COPD: variety
Year: 2015
QVA149 showed significant improvements in lung function and health status and was well tolerated versus glycopyrronium and tiotropium in patients with severe COPD: The SPARK study
Source: International Congress 2014 – Bronchodilators for asthma and COPD
Year: 2014
Can roflumilast improve clinical outcomes in moderate-to-severe chronic obstructive pulmonary disease? A meta-analysis
Source: International Congress 2016 – COPD diagnosis and management
Year: 2016
QVA149 reduces COPD exacerbation rate in various subgroups of patients: The SPARK study
Source: Annual Congress 2013 –New bronchodilators for COPD management
Year: 2013
COPD: Influence of patients’ nutritive status on the exacerbations rate
Source: International Congress 2016 – COPD diagnosis and management
Year: 2016
Improved health outcomes in patients with COPD during 1 yr's treatment with tiotropium
Source: Eur Respir J 2002; 19: 209-216
Year: 2002
LATE-BREAKING ABSTRACT: Glycopyrronium once-daily significantly improves lung function and health status when added to fluticasone/salmeterol in patients with COPD: The GLISTEN study
Source: International Congress 2014 – Latest insights in airway diseases
Year: 2014
Assessing COPD profiles and outcomes by dyspnoea severity
Source: International Congress 2016 – Novel avenues in the treatment of COPD I
Year: 2016
Antagonism of substance P and perception of dyspnea in patients with COPD
Source: Annual Congress 2013 –COPD mechanisms
Year: 2013
QVA149 provides superior peak lung function in patients with COPD
Source: Annual Congress 2013 –Asthma and COPD management: novel clinical findings
Year: 2013
Lung function, symptoms and prescription of inhaled steroids and long acting β2 agonists in patients managed by an integrated COPD team
Source: International Congress 2016 – Novel avenues in the treatment of COPD I
Year: 2016
Are COPD patients with chronic dyspnea and attending pulmonary rehabilitation treated with dual bronchodilatation or not?
Source: International Congress 2016 – Best abstracts in COPD management
Year: 2016
Dual bronchodilation with once-daily QVA149 improves lung function and reduces exacerbations in patients with COPD: The IGNITE trials
Source: Annual Congress 2013 –New clinical trials of asthma and COPD drugs
Year: 2013
Effect of aclidinium bromide on dyspnoea and health status in patients with stable COPD: Phase III data by GOLD 2013 classification
Source: International Congress 2014 – Asthma and COPD management
Year: 2014
The impact of comorbidities on pulmonary rehabilitation outcomes in patients with COPD
Source: International Congress 2016 – Hospitalisation and comorbidities in chronic lung diseases
Year: 2016
Dual bronchodilation with once-daily QVA149 reduces exacerbations, improves lung function and health status versus glycopyrronium and tiotropium in severe-to-very severe COPD patients: The SPARK study
Source: Annual Congress 2013 –New bronchodilators for COPD management
Year: 2013
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept